(Total Views: 252)
Posted On: 03/02/2023 11:30:50 AM
Post# of 61

$GALT News Article - Galectin Therapeutics Provides Final Randomization Status of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis https://marketwirenews.com/news-releases/gale...65026.html


My Twitter: WhyteStocks